CL2014000922A1 - Compuestos derivados de dihidroisoquinolinas o sus sales, como inhibidores de la actividad de las proteinas antiapoptoticas bcl-xl; composicion farmaceutica que los comprende, util para el tratamiento de cancer de vejiga, de cerebro, de mama, de medula osea, colorrectal, de esofago, de ovario, leucemia linfocitica cronica, o cancer de bazo, entre otros. - Google Patents

Compuestos derivados de dihidroisoquinolinas o sus sales, como inhibidores de la actividad de las proteinas antiapoptoticas bcl-xl; composicion farmaceutica que los comprende, util para el tratamiento de cancer de vejiga, de cerebro, de mama, de medula osea, colorrectal, de esofago, de ovario, leucemia linfocitica cronica, o cancer de bazo, entre otros.

Info

Publication number
CL2014000922A1
CL2014000922A1 CL2014000922A CL2014000922A CL2014000922A1 CL 2014000922 A1 CL2014000922 A1 CL 2014000922A1 CL 2014000922 A CL2014000922 A CL 2014000922A CL 2014000922 A CL2014000922 A CL 2014000922A CL 2014000922 A1 CL2014000922 A1 CL 2014000922A1
Authority
CL
Chile
Prior art keywords
dihydroisoquinolines
bcl
esophagus
colorectal
ovarian
Prior art date
Application number
CL2014000922A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Souers
Le Wang
George Doherty
Xilu Wang
Zhi-Fu Tao
Milan Brunko
Aaron R Kunzer
Michael D Wendt
Xiaohong Song
Robin Frey
Todd M Hansen
Gerard Sullivan
Andrew Judd
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CL2014000922A1 publication Critical patent/CL2014000922A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014000922A 2011-10-14 2014-04-11 Compuestos derivados de dihidroisoquinolinas o sus sales, como inhibidores de la actividad de las proteinas antiapoptoticas bcl-xl; composicion farmaceutica que los comprende, util para el tratamiento de cancer de vejiga, de cerebro, de mama, de medula osea, colorrectal, de esofago, de ovario, leucemia linfocitica cronica, o cancer de bazo, entre otros. CL2014000922A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547165P 2011-10-14 2011-10-14
CN2012078372 2012-07-09

Publications (1)

Publication Number Publication Date
CL2014000922A1 true CL2014000922A1 (es) 2014-08-18

Family

ID=47073545

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000922A CL2014000922A1 (es) 2011-10-14 2014-04-11 Compuestos derivados de dihidroisoquinolinas o sus sales, como inhibidores de la actividad de las proteinas antiapoptoticas bcl-xl; composicion farmaceutica que los comprende, util para el tratamiento de cancer de vejiga, de cerebro, de mama, de medula osea, colorrectal, de esofago, de ovario, leucemia linfocitica cronica, o cancer de bazo, entre otros.

Country Status (23)

Country Link
EP (2) EP2768830B1 (en:Method)
JP (2) JP6049738B2 (en:Method)
KR (1) KR102056587B1 (en:Method)
CN (1) CN109535155B (en:Method)
AR (1) AR088328A1 (en:Method)
AU (2) AU2012322818A1 (en:Method)
BR (1) BR112014009052B1 (en:Method)
CA (1) CA2850976C (en:Method)
CL (1) CL2014000922A1 (en:Method)
CO (1) CO6950477A2 (en:Method)
DO (1) DOP2014000074A (en:Method)
EC (1) ECSP14000606A (en:Method)
ES (1) ES2699966T3 (en:Method)
IL (1) IL231926A (en:Method)
MX (2) MX364950B (en:Method)
PE (2) PE20141997A1 (en:Method)
PH (1) PH12014500815B1 (en:Method)
RU (1) RU2594282C2 (en:Method)
SG (2) SG10201606031XA (en:Method)
TW (1) TWI561521B (en:Method)
UY (1) UY34381A (en:Method)
WO (1) WO2013055895A1 (en:Method)
ZA (1) ZA201402555B (en:Method)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
AU2015360621A1 (en) * 2014-12-09 2017-06-29 Abbvie Inc. Bcl-xL inhibitory compounds and antibody drug conjugates including the same
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
CN114173772A (zh) * 2019-04-12 2022-03-11 托尼克斯医药控股公司 Cd40-cd154结合的抑制剂
KR102316961B1 (ko) * 2020-01-29 2021-10-26 프라비바이오 주식회사 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물
EP4251209A1 (en) 2020-11-24 2023-10-04 Novartis AG Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
EP4525925A1 (en) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CA3256012A1 (en) 2022-05-20 2023-11-23 Les Laboratoires Servier ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
WO1997010223A1 (en) 1995-09-15 1997-03-20 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
KR101389246B1 (ko) * 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
ES2525229T3 (es) 2007-02-15 2014-12-19 F. Hoffmann-La Roche Ag 2-aminooxazolinas como ligandos de TAAR1
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
NZ593537A (en) * 2008-12-19 2013-07-26 Genentech Inc Isoquinoline derivatives and methods of use
ES2462715T3 (es) * 2008-12-19 2014-05-26 Genentech, Inc. Compuestos y métodos de uso
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
TWI571466B (zh) 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑

Also Published As

Publication number Publication date
ES2699966T3 (es) 2019-02-13
AU2017206149A1 (en) 2017-08-03
IL231926A0 (en) 2014-05-28
SG10201606031XA (en) 2016-09-29
DOP2014000074A (es) 2014-07-15
PE20141997A1 (es) 2015-01-07
ZA201402555B (en) 2019-10-30
JP2017061535A (ja) 2017-03-30
MX351970B (es) 2017-11-06
PE20181357A1 (es) 2018-08-22
RU2594282C2 (ru) 2016-08-10
EP3266776A1 (en) 2018-01-10
UY34381A (es) 2013-05-31
CN109535155B (zh) 2022-07-12
EP2768830A1 (en) 2014-08-27
JP2014530237A (ja) 2014-11-17
CO6950477A2 (es) 2014-05-20
MX2014004561A (es) 2014-11-14
CA2850976A1 (en) 2013-04-18
KR102056587B1 (ko) 2019-12-18
AU2017206149B2 (en) 2018-11-08
ECSP14000606A (es) 2015-06-30
PH12014500815B1 (en) 2018-04-20
CA2850976C (en) 2020-03-10
SG11201401479SA (en) 2014-07-30
CN109535155A (zh) 2019-03-29
JP6049738B2 (ja) 2016-12-21
JP6337068B2 (ja) 2018-06-06
TW201319065A (zh) 2013-05-16
MX364950B (es) 2019-05-15
IL231926A (en) 2016-11-30
TWI561521B (en) 2016-12-11
NZ623068A (en) 2016-07-29
WO2013055895A1 (en) 2013-04-18
BR112014009052A2 (en) 2017-06-13
RU2014119254A (ru) 2015-11-20
PH12014500815A1 (en) 2014-05-19
AR088328A1 (es) 2014-05-28
EP2768830B1 (en) 2018-08-29
KR20140084174A (ko) 2014-07-04
BR112014009052B1 (pt) 2022-01-04
AU2012322818A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CL2014000922A1 (es) Compuestos derivados de dihidroisoquinolinas o sus sales, como inhibidores de la actividad de las proteinas antiapoptoticas bcl-xl; composicion farmaceutica que los comprende, util para el tratamiento de cancer de vejiga, de cerebro, de mama, de medula osea, colorrectal, de esofago, de ovario, leucemia linfocitica cronica, o cancer de bazo, entre otros.
CL2012003286A1 (es) Compuestos derivados de heerociclos sustituidos, inductores de apoptosis; composicion farmaceutica; y su uso para el tratamiento de diversos cancer, tales como vejiga, cerebro, mamas, medula osea, hepatocelular, linfoma, leucemia linfoblastica, entre otros
CL2014000905A1 (es) Compuestos derivados de acidos carboxilicos de carbamoil-hidroisoquinolinas sustituidas, inhibidores de proteinas antiapoptoticas bcl-xl; composicion farmaceutica; metodo de tratamiento para el cancer de mama, cancer de cuello uterino, cancer colorrectal, cancer hepatocelular, cancer de esofago, leucemias, mielomas, entre otros.
MX380284B (es) Reacciones de macrociclización e intermediarios y otros fragmentos útiles en la síntesis de macrólidos de halicondrina.
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
MX2016001963A (es) Metodo de seleccion.
DOP2016000271A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
EP3929197C0 (en) INTERMEDIATES FOR THE SYNTHESIS OF HETEROBICYCLIC MICROBIOCIDAL DERIVATIVES
ITUB20153803A1 (it) Macchina per la produzione di cartucce per sigarette elettroniche.
CL2014000130A1 (es) Compuestos derivados de anillos de piridinas fusionados, inhibidores de btk; composicion farmaceutica; combinacion farmaceutica; y su uso para trastornos mediado por btk como artritis y sus variantes, trastornos hematologicos, enfermedad de crohn, entre otras.
EP3603281A4 (en) IMPROVED SRS FREQUENCY JUMP SCHEME FOR 5G NR
UY34145A (es) Compuestos inhibidores de metaloenzimas
EP2931971A4 (en) WET PAD MATERIAL MICROFIBRILLED MATERIAL COMPOSITION
EP3515335A4 (en) PIN PLACEMENT HOLDER FOR SURGICAL PIN INSERTION DEVICE
ZA201904422B (en) Track support rail for supporting track assembly of machine, track support
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
BR112016021473A2 (pt) Derivação de informação de instalação de id temporal sps para fluxos de bits de multicamadas
EP2819693A4 (en) ANTICANCER BITHERAPY BASED ON OX40 / IL-2 AGONIST
BR112014031787A2 (pt) composição, métodos de substituição e para produção de refrigeração e equipamento de refrigeração.
LT4005588T (lt) Kompozicija, skirta kontroliuojamai kiaušidžių stimuliacijai
FR3039063B1 (fr) Procede d'enrichissement en pongamol d'huile de karanja
BR112015024558A2 (pt) método para tratamento de leucemia mieloide.
CL2015003037A1 (es) Derivados de triazina